Sipavibart - AstraZeneca
Alternative Names: AZD-3152Latest Information Update: 04 Jul 2024
At a glance
- Originator RQ Bio
- Developer AstraZeneca; RQ Bio
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Coronavirus spike glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration COVID 2019 infections
Most Recent Events
- 01 Jul 2024 Preregistration for COVID-2019 infections (Prevention) in European Union (IM)
- 01 Jul 2024 European Medicines Agency (EMA) accepts MAA for sipavibart for COVID-2019 infections (Prevention), under an accelerated assessment procedure
- 17 May 2024 AstraZeneca completes the phase II NOVELLA trial in COVID-2019 infections (Prevention) in Russia (IM) (NCT06057064)